Patent · US Active

Fused tricyclic compounds as Raf kinase inhibitors

US10576087B2 · kind B2 · utility

2Cited by
3References
16Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 29, 2018
Grant dateMar 3, 2020
Priority date—
Expiry dateJan 29, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D519/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.